MOTS-c: What the Research Actually Shows
A mitochondrial-encoded peptide with well-characterized mouse data, a genuinely interesting human signal (exercise raises it, and low levels track with worse cardiometabolic disease), and, as of a completed randomized trial of a closely related analog molecule, the first real evidence that boosting this signal can move human liver and metabolic markers. A randomized trial of MOTS-c itself is now enrolling. Here's exactly what's been shown in people, what's mouse-only, what comes from a related but not identical molecule, and where every line actually sits.
A Peptide the Mitochondrion Makes for Itself
MOTS-c is a 16-amino-acid peptide, but it isn't made from a gene in the cell's nucleus like almost everything else in the body. It's encoded by a short open reading frame inside the mitochondrial genome itself, specifically within the 12S rRNA gene, and was first identified in 2015. It belongs to a small class of "mitochondrial-derived peptides," signals the mitochondrion produces and exports on its own, that appear to report the cell's metabolic and energy status back to the rest of the cell and to other tissues. Functionally, MOTS-c has been described as an exercise mimetic: it activates AMPK, the cell's central energy-sensing enzyme, through a distinct mechanism (inhibiting the folate cycle and de novo purine biosynthesis), and its levels rise sharply in skeletal muscle and blood in response to physical exertion, in mice and in people.
Evidence Summary
Mechanism, Mouse Efficacy Data, and Now a First Human Trial Signal, Graded Separately
Discovery and Mechanism
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism. 2015;21(3):443-454. doi: 10.1016/j.cmet.2015.02.009. PMID: 25738459. The paper that first identified MOTS-c and characterized what it does. In mice, MOTS-c activated AMPK in skeletal muscle, its primary site of action, by inhibiting the folate cycle and purine biosynthesis, and administration prevented both age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity. This is the foundational paper the rest of the MOTS-c literature builds on. Mouse study throughout, no human arm.
Mouse Model, Mechanistic & Metabolic Outcomes · Endpoint: AMPK Activation, Insulin Resistance, Obesity, Mouse OnlyExercise, Aging, and Healthspan
Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications. 2021;12:470. doi: 10.1038/s41467-020-20790-0. This paper is unusual in the MOTS-c literature for actually including people. In young, healthy, sedentary male volunteers, a single session of stationary cycling increased muscle MOTS-c protein nearly 12-fold and circulating MOTS-c roughly 1.5- to 1.6-fold, real confirmation that exercise drives this peptide's production in humans, not just in mice. The therapeutic side of the same paper, daily injected MOTS-c improving treadmill performance, grip strength, gait, body composition, and metabolic flexibility, including in mice over 30 months old, was tested only in mice. Read the exercise-response finding as human physiology; read the performance and healthspan benefits as mouse data.
Human Exercise-Response Data + Mouse Administration Data · Endpoint: Endogenous Response (Human) & Functional/Healthspan Outcomes (Mouse Only)Insulin Sensitivity and Metabolic Signaling
Kim SJ, Miller B, Mehta HH, Xiao J, Wan J, Arpawong TE, Yen K, Cohen P. "The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity." Physiological Reports. 2019;7(13):e14171. doi: 10.14814/phy2.14171. In aged and diet-induced obese mice, injected MOTS-c improved insulin sensitivity and shifted plasma metabolomic markers, sphingolipid, monoacylglycerol, and dicarboxylate metabolism, away from a pattern otherwise associated with obesity and type 2 diabetes. Mouse study only.
Mouse Model, Metabolomics · Endpoint: Insulin Sensitivity, Mouse OnlyExercise Performance After a Single Dose
Hyatt JK. "MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose." Physiological Reports. 2022;10(13):e15377. PMID: 35808870. A single injected dose of MOTS-c (15 mg/kg) improved treadmill running time and distance in untrained mice, and chronic voluntary exercise raised muscle MOTS-c protein 1.5- to 5-fold, an increase that persisted for several weeks of detraining. Mouse study throughout.
Mouse Model · Endpoint: Exercise Performance, Mouse OnlyA Third Organ System: Vascular and Cardiac Protection in a Rat Model
Wei M, Gan L, Liu Z, Liu L, Chang JR, Yin DC, Cao HL, Su XL, Smith WW. "Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway." Cardiorenal Medicine. 2020;10(1):42-50. doi: 10.1159/000503224. In rats with vitamin D3- and nicotine-induced vascular calcification, four weeks of daily injected MOTS-c reduced vascular calcium deposition by roughly 56%, normalized the abnormal cardiac wall thickening and chamber dimensions the calcification had caused, and lowered elevated blood pressure, working through the same AMPK pathway the discovery paper above described. This extends MOTS-c's demonstrated mechanism beyond fat and muscle into the cardiovascular system, a third organ system responding to the same signal. Rat study only, no human arm.
Rat Model · Endpoint: Vascular Calcification, Cardiac Structure, Blood Pressure, Animal OnlyHuman Data: Circulating MOTS-c as a Cardiometabolic Biomarker
Two independent human studies have measured endogenous MOTS-c as a blood biomarker, not as a treatment, in people with cardiometabolic disease. Ikonomidis I, Katogiannis K, Kyriakou E, et al. "β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease." Journal of Thrombosis and Thrombolysis. 2020;49(3):365-376. doi: 10.1007/s11239-020-02060-4. In 121 people with type 2 diabetes followed for 2 years after coronary revascularization, those with both high platelet reactivity and low circulating MOTS-c (below 167 ng/mL) had roughly 4.4 times the risk of a major adverse cardiac event. Separately, Yaşar E, Çakmak T, Bayramoğlu A, et al. "MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease." European Review for Medical and Pharmacological Sciences. 2022;26(16):5676-5682. doi: 10.26355/eurrev_202208_29501. found circulating MOTS-c was substantially lower in 92 people with confirmed coronary artery disease than in 92 people with normal coronary arteries on angiography (111 vs. 161, P<.001), with a MOTS-c level below roughly 131 predicting the presence of disease with 80% sensitivity. Both studies show real associations between endogenous MOTS-c and human cardiometabolic disease. Neither tested MOTS-c as a treatment, and an inverse association with disease severity doesn't establish that raising MOTS-c would improve outcomes, that causal question hasn't been tested in humans.
Human, Observational · Endpoint: Endogenous Biomarker Association, Not InterventionalThe First Human Trial Signal: A Modified Analog Improves Liver and Metabolic Markers
Loomba R, Hompesch M, Salazar H, Lawitz E, Kam J, Cundy KC. "CB4211, a Novel Analog of MOTS-c, Improves Markers of Liver Injury and Metabolism in Obese Subjects with Nonalcoholic Fatty Liver Disease." Presented as a late-breaker poster at AASLD The Liver Meeting, 2021 (Poster LB5). CB4211 is a modified, improved analog of MOTS-c developed for drug delivery, not the native peptide itself, engineered to extend how long it activates the insulin receptor. In a double-blind, randomized, placebo-controlled trial, 23 adults with obesity and nonalcoholic fatty liver disease received four weeks of daily subcutaneous CB4211 (25 mg) or placebo under inpatient, diet-controlled conditions. ALT fell 21% with CB4211 versus 4% with placebo, AST fell 28% versus 11%, and fasting glucose fell 6% versus no change, all statistically significant improvements over placebo. Liver fat by MRI improved similarly in both groups, so no advantage was shown there, and body weight showed only a non-significant trend toward reduction. Treatment was well tolerated, with no serious adverse events; the main side effect was mild-to-moderate injection-site reactions. This is real, randomized, placebo-controlled human evidence that boosting MOTS-c signaling changes human liver and metabolic physiology, from a modified analog rather than the molecule sold as MOTS-c, and the results were presented at a major medical conference rather than published yet in a peer-reviewed journal.
Human, Randomized Controlled Trial (Analog Molecule, Not Native MOTS-c) · Endpoint: Liver Enzymes, Glucose, Liver Fat, Conference-PresentedA Real Trial of MOTS-c Itself Is Now Enrolling
A Phase 2a, randomized, double-blind, placebo-controlled trial of MOTS-c, the native peptide itself, is currently recruiting (ClinicalTrials.gov NCT07505745, sponsor Hudson Biotech). It's testing whether 12 weeks of once-daily subcutaneous MOTS-c improves insulin sensitivity, measured by an OGTT-derived Matsuda Index, in about 120 adults with prediabetes and overweight or obesity, alongside safety, immunogenicity, HbA1c, fasting and 2-hour glucose, body weight, and waist circumference. The trial began enrolling in February 2026, with primary results expected in early 2027. No results exist yet, this is a trial in progress, not a completed finding, but it directly answers the question this page has asked all along: whether anyone would actually test administered MOTS-c in people. Now, for the first time, someone is.
Human, Randomized Controlled Trial (Native MOTS-c), Currently Recruiting · Endpoint: Insulin Sensitivity, Safety, Not Yet CompletedWhat the Research Doesn't Yet Show
No completed trial has ever administered native MOTS-c to a person as a treatment, and that's still true today. What's changed is the trajectory. A modified analog of MOTS-c has already shown a real, statistically significant effect on human liver enzymes and glucose in a randomized, placebo-controlled trial, and a Phase 2a trial of MOTS-c itself is now recruiting. Neither of those facts proves that native MOTS-c, dosed and delivered the way it's sold today, will do the same thing in people: an analog engineered for a specific pharmacological purpose isn't guaranteed to behave identically to the native peptide, and a trial that's still enrolling hasn't reported results. But the absence of outcome data is no longer the whole story. A plausible mechanism, now demonstrated across three organ systems in animals, has produced a real positive human signal from a related molecule, which is exactly the kind of evidence that makes running the next trial worthwhile rather than a reason to expect nothing. Whether the mouse and rat findings, and the analog's human results, translate cleanly to native MOTS-c, at what dose, by what route, and with what long-term safety profile, is what the currently enrolling trial exists to answer.
Investigational, not FDA-approved for any indication.
How This Fits the Cellular Medicine Framework
MOTS-c sits at an unusual point in this framework compared to most hormones and peptides. Most signals act on a cell-surface receptor and eventually influence mitochondrial function downstream. MOTS-c is a signal the mitochondrion itself encodes and exports, sitting at the metabolism-and-mitochondrial-function level directly rather than converging on it from outside. Its mechanism, folate-cycle and purine-biosynthesis inhibition activating AMPK, is cellular energy sensing responding to a signal mitochondria generate about their own status.
That the same AMPK-activation mechanism now shows up across three separate organ systems, fat and muscle metabolism, skeletal muscle exercise physiology, and cardiovascular protection, and that a closely related molecule has already produced a real, statistically significant result in a human trial, is a genuinely encouraging convergence. It's the kind of pattern that makes a peptide worth taking through the human trial that's now finally underway, not a reason to expect the answer before that trial reports.
AMPK activation is also a core piece of redox biology: it is one of the cell's main sensors for shifts in energy and oxidative status, which is why a mitochondrially-generated signal that activates it is worth reading in that broader context, not in isolation.
References
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009 · PMID: 25738459
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. doi:10.1038/s41467-020-20790-0
- Kim SJ, Miller B, Mehta HH, Xiao J, Wan J, Arpawong TE, Yen K, Cohen P. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171. doi:10.14814/phy2.14171
- Hyatt JK. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose. Physiol Rep. 2022;10(13):e15377. PMID: 35808870
- Ikonomidis I, Katogiannis K, Kyriakou E, et al. β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. J Thromb Thrombolysis. 2020;49(3):365-376. doi:10.1007/s11239-020-02060-4
- Yaşar E, Çakmak T, Bayramoğlu A, et al. MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease. Eur Rev Med Pharmacol Sci. 2022;26(16):5676-5682. doi:10.26355/eurrev_202208_29501
- Wei M, Gan L, Liu Z, Liu L, Chang JR, Yin DC, Cao HL, Su XL, Smith WW. Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway. Cardiorenal Med. 2020;10(1):42-50. doi:10.1159/000503224
- Loomba R, Hompesch M, Salazar H, Lawitz E, Kam J, Cundy KC. CB4211, a Novel Analog of MOTS-c, Improves Markers of Liver Injury and Metabolism in Obese Subjects with Nonalcoholic Fatty Liver Disease. Late-breaker poster, AASLD The Liver Meeting, 2021 (Poster LB5).
- MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. ClinicalTrials.gov identifier NCT07505745. Sponsor: Hudson Biotech. clinicaltrials.gov/study/NCT07505745
Explore the Rest of the Knowledge Center
Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.